All of the included studies were observational cohort studies. Each study included pregnant women with either gestational diabetes or pregestational diabetes who were on insulin glargine and a control ...

Mylan Pharmaceuticals has recalled some insulin-glargine injection pens because they may be missing labels. According to an announcement with the U.S. Food and Drug Administration, the lack of a label ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved insulin glargine-aglr, a second biosimilar to Sanofi’s insulin glargine, to improve glycemic ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

The use of insulin glargine, (a single injection of daily insulin) is as effective at controlling blood sugar for people with diabetes as insulin lispro (which has to be injected up to three times a ...

March 11, 2011 — Insulin degludec (Novo Nordisk), a novel, ultra-long-acting basal formulation, provides comparable glycemic control to insulin glargine without additional adverse events and may ...

The designation means that pharmacists can switch patients to the less-expensive version of insulin without seeking approval from the clinician. The FDA late Thursday approved the country’s first ...

The FINANCIAL — Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on December 15 that BASAGLAR (insulin glargine injection 100 units/mL) is available by prescription in ...

As part of the Biosimilars Initiative, British Columbia, Canada, implemented a mandatory switch to biosimilar insulin glargine for patients covered by the province’s drug plan. Multiple Canadian ...

Lantus (insulin glargine) is a brand-name prescription drug used to treat diabetes. As with other medications, Lantus can interact with alcohol and certain other drugs. An interaction occurs when one ...

(Reuters) - Sanofi SA, whose top-selling Lantus helps diabetics control blood sugar levels, has filed a lawsuit accusing Eli Lilly and Co of infringing seven patents related to insulin and devices ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the second interchangeable insulin glargine biosimilar, Rezvoglar, to improve glycemic control ...